DDIT3 and diffuse large B-cell lymphoma: Targeting nucleolin with the specific aptamer AS1411 significantly increased the cytotoxicity of Dox toward DLBCL cells; this finding shows the clinical importance of R-CHOP-based therapy in improving the prognosis of DLBCL patients.139